Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

An Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

An Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

18 years - 99 years
All genders
Interventional
Open label extension trial of CVL-865 in adults with drug-resistant focal onset seizures to learn how well the investigational drug works and how safe it is for long-term epilepsy treatment. Participants will answer questions; undergo physical-neuro exams; vitals; ECG collection; blood draws; urine collection; questions about the study drug; and …
Learn More
Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

18 years - 99 years
All genders
Phase 1
Interventional
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Learn More
The Impact of COVID 19 on Laryngeal Function Voice Communication and Quality of Life

The Impact of COVID 19 on Laryngeal Function Voice Communication and Quality of Life

18 years - 99 years
All genders
This project aims to create a national cohort of COVID-19 ICU survivors, quantify the longer-term burden of COVID-19 infection and treatment on laryngeal function, voice, communication and quality of life within the cohort and identify potential intervention targets to prevent post-intubation laryngeal injuries. Subjects will be recruited from Penn's Otorhinolaryngology …
Learn More
ANDROMEDA-SHOCK-2 Trial

ANDROMEDA-SHOCK-2 Trial

18 years - 99 years
All genders
Septic shock is a disease of the circulatory system representing a complication of serious infections, and is associated with a very high mortality, since around 1/3 of patients with this condition die. This disease produces a series of alterations in the body, including failure of the heart, kidneys, liver, among …
Learn More
The NICU Antibiotics and Outcomes Trial (NANO)

The NICU Antibiotics and Outcomes Trial (NANO)

99 years or below
All genders
The goal of the NANO trial is to study the longstanding clinical practice of empirically administering intravenous antibiotics to extremely low birthweight (ELBW) infants in the first days of life. In this 802-subject multicenter placebo-controlled randomized clinical trial, the hypothesis to be tested is that the incidence of adverse outcomes …
Learn More
Cardiac Amyloidosis Registry Study ("CARS")

Cardiac Amyloidosis Registry Study ("CARS")

18 years - 89 years
All genders
Observational
This registry is a retrospective observational, multi-center study designed to collect data and analyze data retrospectively on patients with AL or TTR cardiac amyloidosis. Subjects under the care of the local investigator will be identified and consented. No patient visits or patient procedures will be required for the purpose of …
Learn More
Study to Assess the Efficacy and Safety of BST-236 in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

Study to Assess the Efficacy and Safety of BST-236 in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

18 years - 99 years
All genders
Phase 2
Interventional
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy.
Learn More
Study of Regn4336 administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer

Study of Regn4336 administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer

18 years - 99 years
Male
Interventional
This research study is designed to learn more about the safety and effectiveness of REGN4336 alone or in combination with cemiplimab given to individuals who have been diagnosed with Prostate Cancer.
Learn More
Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)

Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)

18 years - 99 years
All genders
Phase 2
Interventional
This is a randomized phase 2 open label study of sacituzumab govitecan +/- pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer and who have not received a prior PD-1/L1 inhibitor
Learn More
Study of lurbinectedin efficacy and safety in participants with advanced or metastatic solid tumors

Study of lurbinectedin efficacy and safety in participants with advanced or metastatic solid tumors

18 years - 99 years
All genders
Phase 2
Interventional
This research study is designed to learn more about the safety and effectiveness of lurbinectedin given to individuals who have been diagnosed with advanced (metastatic and/or unresectable) solid tumors.
Learn More
1071 - 1080 of 1243